Make the silent threat visible
Glaucoma can progress before patients notice symptoms. Healthcare leaders can turn awareness into earlier diagnosis, closed-loop referral, affordable treatment, and sustained vision protection.
The leadership signal
January is National Glaucoma Awareness Month. The National Eye Institute describes glaucoma as a group of eye diseases that can cause vision loss and blindness by damaging the optic nerve. Symptoms can begin so slowly that people do not notice them. A comprehensive dilated eye examination is the most reliable way to detect the disease.
CDC reports that about 3 million Americans have glaucoma and that roughly half do not know it. Early treatment cannot restore vision already lost, but it can often stop or slow further damage. The executive opportunity is therefore clear. Health systems must find risk earlier and ensure that detection leads to timely, sustained care.
The silent-threat problem is operational
Glaucoma does not usually announce itself early. That means traditional symptom-driven access will miss people until irreversible damage has occurred. Yet an isolated screening event is also insufficient. A concerning finding must be interpreted, confirmed, communicated, referred, treated, and monitored over time.
Organizations frequently lose reliability at the handoffs. Primary-care records may not capture eye-care results. Community screening may identify risk without a completed ophthalmology visit. Patients may start eye drops without support for cost, technique, side effects, or daily adherence. Missed follow-up may be documented as noncompliance instead of treated as a system signal.
Find
Identify patients at higher risk through age, family history, diabetes, blood pressure, demographic risk, access barriers, and local prevalence.
Close
Assign responsibility for every abnormal screen, referral, diagnostic test, and overdue follow-up.
Sustain
Support treatment access, medication technique, monitoring, transportation, and communication over the life of the disease.
A four-stage glaucoma reliability pathway
Identify risk
Use primary care, diabetes programs, emergency encounters, senior services, and community partners to recognize patients who may benefit from comprehensive eye care.
Complete examination
Move patients from outreach or screening to a comprehensive dilated exam and clinician-directed diagnostic assessment.
Initiate treatment
Ensure the patient understands the diagnosis, goal, medication or procedure plan, cost, side effects, technique, and next appointment.
Monitor progression
Track pressure, optic-nerve findings, visual fields, adherence, missed visits, and treatment escalation through closed-loop follow-up.
Target risk without narrowing access
Anyone can develop glaucoma, but risk is not evenly distributed. CDC identifies higher-risk groups that include Black people over age 40, all people over age 60, people with a family history of glaucoma, and people with diabetes. CDC also notes that Black people are 6 to 8 times more likely to develop glaucoma than White people, while people with diabetes face about twice the risk of people without diabetes.
Those clinical risks interact with access barriers. CDC-supported programs identify people who are uninsured or underinsured, people living in poverty, and residents of rural communities with limited resources as groups at higher risk of blindness from glaucoma. A risk-based strategy therefore requires more than education. It needs affordable examinations, transportation solutions, trusted community access points, language support, referral navigation, and sufficient specialist capacity.
Executives should not use race or ethnicity as a substitute for individualized assessment. They should use population data to identify inequities in access and outcomes, direct resources to underserved communities, and evaluate whether redesigned pathways close gaps.
Six executive decisions that protect vision
Name a vision-health pathway owner
Give one accountable leader responsibility for risk identification, referral closure, specialty capacity, treatment access, equity, and performance reporting.
Embed risk prompts in routine care
Use age, family history, diabetes, hypertension, and locally relevant risk factors to support eye-care conversations and referrals in primary and chronic-care settings.
Close every abnormal result
Measure time from concerning screening or examination findings to patient contact, comprehensive evaluation, documented diagnosis, and a treatment or surveillance plan.
Build treatment-access support
Address medication affordability, pharmacy access, administration technique, side effects, transportation, health literacy, and referral scheduling before labeling patients nonadherent.
Integrate eye and medical records
Return ophthalmology findings and follow-up expectations to primary-care and diabetes teams, with clear ownership for overdue care and clinically important changes.
Fund equitable capacity
Use community partnerships, teleophthalmology where clinically appropriate, mobile access, navigators, and specialty scheduling protections to reach high-risk populations.
Treatment is a long-term operating commitment
NEI describes medicines, laser treatment, and surgery as treatment options for glaucoma. Prescription eye drops are common and work by lowering eye pressure to help prevent further optic-nerve damage. Laser procedures can improve fluid drainage, and surgery may be considered when medicines and laser treatment are insufficient. Treatment selection belongs to the patient and eye-care clinician.
For health-system leaders, the operational issue is persistence. Eye drops may not make patients feel better or improve existing vision, so the benefit can feel invisible. NEI warns that stopping treatment can allow vision loss to progress. Organizations should monitor medication access, refill barriers, administration technique, adverse effects, follow-up attendance, and escalation when treatment goals are not met.
The executive glaucoma scorecard
| Domain | Measure | Executive question |
|---|---|---|
| Risk reach | Higher-risk patients offered or connected to comprehensive eye care | Who is missing from the pathway? |
| Referral closure | Days from referral or concerning finding to completed examination | Who owns each open referral? |
| Diagnostic closure | Completed assessment with diagnosis and documented plan | Are we counting referrals or resolved episodes? |
| Treatment access | Time to medication, laser, surgery, or surveillance plan | Which costs and capacity limits delay care? |
| Continuity | On-time monitoring, refill continuity, missed-visit recovery | Can deterioration occur without an escalation? |
| Equity | All measures stratified by locally relevant population and access variables | Where does the pathway perform differently? |
A practical 90-day leadership plan
Map and baseline
- Map the pathway from risk identification through ongoing treatment.
- Quantify open referrals, delayed exams, and missed follow-up.
- Stratify measures to identify access and outcome gaps.
- Interview patients about cost and navigation barriers.
Standardize closure
- Assign owners and escalation timelines.
- Create abnormal-result and missed-visit work queues.
- Standardize patient education and medication-technique support.
- Connect eye care with primary and diabetes-care records.
Pilot and govern
- Pilot in one high-risk primary-care population.
- Review referral closure and equity weekly.
- Test navigator, transportation, and affordability supports.
- Report unresolved barriers to the quality committee.
Conclusion: make the silent threat visible
National Glaucoma Awareness Month should not end with a reminder to schedule an eye exam. It should prompt executives to examine whether their organizations can identify risk, complete evaluation, initiate appropriate treatment, and protect follow-up over time.
Glaucoma-related vision loss is often irreversible, but much of the progression can be prevented through earlier detection and sustained care. Leaders can make that promise operational by closing referrals, funding equitable access, supporting treatment persistence, and measuring the entire pathway instead of isolated encounters.
Authoritative resources
- National Eye Institute: Glaucoma Awareness Month
- National Eye Institute: Glaucoma
- CDC: About Glaucoma
- CDC: Glaucoma Detection Programs
- National Eye Institute: Glaucoma Medicines
- National Eye Institute: Laser Treatment
- Prevent Blindness: 2026 Glaucoma Awareness Month
This executive brief supports organizational planning and education. It does not replace individualized eye care, diagnosis, treatment, or follow-up advice.
